Autosomal dominant hypocalcemia
MONDO:0018543Autosomal dominant hypocalcemia (AD hypocalcemia) is a disorder of calcium homeostasis characterized by variable degrees of hypocalcemia with abnormally low levels of parathyroid hormone (PTH) and persistent normal or elevated calciuria.
Also known as: hypocalcemia, AD hypocalcemia, hypocalcemia, autosomal dominant
13 clinical trials for this condition and its sub-types, 9 tagged with Autosomal dominant hypocalcemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Autosomal dominant hypocalcemia
-
Autosomal dominant hypocalcemia 1 4 trials
-
New drug aims to fix calcium levels in rare genetic disease
Disease control OngoingThis study tests a new drug called encaleret against usual treatments for people with a rare genetic condition called autosomal dominant hypocalcemia type 1 (ADH1), which causes low blood calcium and high urine calcium. About 67 participants will receive either encaleret or stand…
Phase 3 • Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Calcium clotting trial for trauma patients abandoned
Disease control CancelledThis study was designed to see if giving calcium right away to trauma patients who need large blood transfusions could help their blood clot better, reduce the need for more transfusions, and improve survival. The trial was withdrawn before enrolling any participants, so no resul…
Phase 3 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New study monitors rare calcium disorder to better understand its long-term effects
Knowledge-focused OngoingThis study is for people with autosomal dominant hypocalcemia types 1 or 2, rare genetic conditions that cause low blood calcium. Researchers will collect past and future health data from 95 participants to learn how the disease changes over time. The goal is to better understand…
Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC